Biomarker Feedback to Motivate Cessation in Pregnancy (MAW Phase 3)
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) - Phase 3 Pilot Clinical Trial
研究概览
地位
详细说明
Developing effective tobacco cessation interventions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobacco-related cancer health disparities. The proposed project builds on the investigators' successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. The investigators propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 the investigators will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, the investigators will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 60 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance the investigators' understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.
This is the third and final phase of the project.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alaska
-
Anchorage、Alaska、美国、99577
- Alaska Native Tribal Health Consortium
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Alaska Native
- 18 years or older
- provide written informed consent
- be currently pregnant and at <24 weeks gestation
- reside in Anchorage and plan to deliver at the ANMC
- current tobacco user defined as any use of Iqmik, commercial ST, and/or cigarettes during the past 7 days.
Exclusion Criteria:
- use of using nicotine replacement therapy or medications for tobacco cessation or participation in a behavioral cessation program within the past 30 days
- another woman from the same household has enrolled.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Control condition
Control behavioral phone-based smoking cessation intervention
|
phone-based behavioral smoking cessation counseling
|
|
实验性的:Biomarker Feedback Intervention
Biomarker feedback plus behavioral phone-based smoking cessation intervention
|
Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
smoking abstinence in late pregnancy (self-reported abstinence verified with cotinine)
大体时间:at week 36 gestation or greater up to the time of delivery
|
self-reported abstinence verified with cotinine
|
at week 36 gestation or greater up to the time of delivery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Self-efficacy (Self-reported confidence scale)
大体时间:at week 36 gestation or greater up to the time of delivery
|
Self-reported confidence scale
|
at week 36 gestation or greater up to the time of delivery
|
合作者和调查者
赞助
合作者
调查人员
- 首席研究员:Christi A Patten, PhD、Mayo Clinic
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.